Zobrazeno 1 - 10
of 30
pro vyhledávání: ''
Autor:
Hervé Dombret, Simon Durrant, Christopher Larry Bacon, Qui Tran, Max S. Topp, Andre C. Schuh, Zachary Zimmerman, Hagop M. Kantarjian, Andrew H. Wei
Publikováno v:
Leukemialymphoma. 60(9)
Outcomes for adults with relapsed/refractory acute lymphoblastic leukemia (ALL) are poor with chemotherapy, particularly in later salvage. The TOWER study examined survival, remission, bridge to allogeneic hematopoietic stem cell transplantation (HSC
Autor:
Arinobu Tojo, Masamichi Isobe, Seiko Kato, Takaaki Konuma, Mai Mizusawa, Kazuaki Yokoyama, Maki Oiwa-Monna, Satoshi Takahashi
Publikováno v:
Leukemialymphoma. 60(9)
Genetic mutation is one of the most powerful prognostic factors for adult patients with acute myeloid leukemia (AML). The FMS-like tyrosine kinase 3 (FLT3) gene mutations, including internal tandem...
Autor:
Vincent Parinet, Dorothée Selimoglu-Buet, Nicolas Noel, Nathalie Droin, Marc Humbert, Nolwenn Lucas, Olivier Lambotte, Eric Solary, Véronique Saada
Publikováno v:
Leukemialymphoma. 58(12)
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic disorder that associates dysplastic and proliferative features. Tissue inflammatory disorders occur in a fraction of CMML patients during the course of their disease. Here, we describe
Autor:
Soo-Hyun Kim, Kyung-Mi Kee, Dong-Wook Kim, Hee-Jeong Hwang, Hye-Young Song, Mi-Young Lee, Hae-Lyun Yoo, Ki-Hoon Kang, Sung-Eun Lee, Soo Young Choi, Eun-Jung Jang
Publikováno v:
Leukemialymphoma. 59(1)
We conducted this study to identify the factors for predicting poor outcomes in chronic myeloid leukemia patients who failed to achieve a 3-month early molecular response (EMR). Of the 413 newly diagnosed, chronic phase, chronic myeloid leukemia pati
Autor:
Gregory Koval, Frederick R. Appelbaum, Barry K. Moser, Martin S. Tallman, Nicholas Holowka, Robert E. Gallagher, Dorie Sher, Wendy Stock, Richard A. Larson, Kabir Gulati, Xavier Poiré, Clara D. Bloomfield, Bayard L. Powell, Elisabeth Paietta, Kristina Laumann, Cheryl L. Willman
Publikováno v:
Leukemialymphoma. 55(7)
The addition of arsenic trioxide (ATO) to frontline therapy of acute promyelocytic leukemia (APL) has been shown to result in significant improvements in disease-free survival (DFS). FLT3 mutations are frequently observed in APL, but its prognostic s
Autor:
Karen W.L. Yee, Donna E. Hogge, Liang Piu Koh, Keith B. Glaser, Xiaohui Li, Evelyn McKeegan, Wendy Stock, Eunice S. Wang, Dawn M. Carlson, Daniel H. Albert, Sari H. Enschede, Rajendra S. Pradhan, Matthew Dudley
Publikováno v:
Leukemialymphoma. 53(8)
Linifanib, a potent oral inhibitor of fms-like tyrosine kinase 3 (FLT3) and vascular endothelial growth factor receptor tyrosine kinases, has demonstrated promising preclinical single-agent and synergistic anti-leukemic activity in combination with c
Publikováno v:
Leukemialymphoma. 53(6)
Treatment of hairy cell leukemia (HCL) with cladribine induces durable remissions. Common toxicities are myelosuppression and immunosuppression with low counts of CD4 + T cells. Skin rash (SR) is seldom described. We collected clinical and laboratory
Autor:
Seon Yang Park, Yeo Kyeoung Kim, Joo Seop Chung, Joon Seong Park, Sang Kyun Sohn, Hyeoung Joon Kim, Eunkyung Park, Ho In Kim, Ki Seong Eom, Moo Rim Park, Jinny Park, Joon Ho Moon, June-Won Cheong, Myung Soo Hyun, Sung-Soo Yoon, Hun Mo Ryoo, Min Kyoung Kim, Sukjoong Oh, Chul Soo Kim, Soo Mee Bang, Byung Soo Kim, Hawk Kim, Dong Hwan Kim, Chul Won Jung, Young Don Joo, Yoo Hong Min, Hong Ghi Lee, Deog Yeon Jo, Dae Young Zang, Jong Ho Won
Publikováno v:
Leukemialymphoma. 52(6)
To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or molecular responses, we measured trough IM levels in patients with chronic myeloid leukemia, chronic phase (CML-CP), at 6 months of treatment with a standard d
Autor:
Seok Jin Kim, Young Hyeh Ko, Jung A Kim, Do-Hyun Nam, Kihyun Kim, Won Seog Kim, In-Gu Do, Juyoun Jin
Publikováno v:
Leukemialymphoma. 52(2)
Hypoxia-associated proteins are commonly expressed as a consequence of disturbances in microcirculation. However, the clinical relevance of the proteins has never been studied in primary central nervous system lymphoma (PCNSL). The expression of hypo
Autor:
Manuel Hein, Monika Engelhardt, Gabriele Ihorst, Ba Thanh-Truc Ngo, Dagmar Wider, Marie Follo, Julia Felthaus, Ralph Wäsch
Publikováno v:
Leukemialymphoma. 51(9)
Cyclins D1, D2, and D3 (CCND1, 2, 3) are regulated by proteasomal degradation. Their overexpression in multiple myeloma (MM) has prognostic value. We performed this pilot study to analyze a possible association between CCND1-3 overexpression and resp